{"id":"gemcitabine-nimotuzumab-toripalimab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Rash"},{"rate":"10-30%","effect":"Pruritus"},{"rate":"5-20%","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL4297843","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gemcitabine works by incorporating itself into DNA, causing DNA damage and inhibiting cancer cell growth. Nimotuzumab binds to EGFR, preventing it from interacting with its ligands and thereby inhibiting tumor growth. Toripalimab binds to PD-1, preventing it from interacting with its ligands and thereby inhibiting the immune system's ability to recognize and attack cancer cells.","oneSentence":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while nimotuzumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and toripalimab is a PD-1 inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:50.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Pancreatic cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT06509009","phase":"PHASE2","title":"Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-08-30","conditions":"Nasopharyngeal Carcinoma by AJCC V8 Stage","enrollment":30},{"nctId":"NCT06561763","phase":"PHASE3","title":"TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-20","conditions":"High Risk Locally Advanced Nasopharyngeal Carcinoma","enrollment":416},{"nctId":"NCT06026878","phase":"PHASE3","title":"GNT Induction Treatment in Locally Advanced NPC","status":"RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2023-09-01","conditions":"Nasopharyngeal Carcinoma","enrollment":228}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GNT"],"phase":"phase_3","status":"active","brandName":"gemcitabine,nimotuzumab, toripalimab","genericName":"gemcitabine,nimotuzumab, toripalimab","companyName":"Air Force Military Medical University, China","companyId":"air-force-military-medical-university-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while nimotuzumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and toripalimab is a PD-1 inhibitor. Used for Non-small cell lung cancer, Pancreatic cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}